Laura Sepp-Lorenzino - 28 Apr 2026 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Reporting relationship: Director
Issuer ticker: LXEO
Reported as of: 28 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Apr 2026, 16:01:55 UTC
Prior SEC filing: 04 Jun 2025
Next SEC filing: 02 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Youjin Choi, Attorney-in-Fact

Key filing fact

Laura Sepp-Lorenzino filed Form 4 for Lexeo Therapeutics, Inc. (LXEO) on 30 Apr 2026.

Key facts

This page summarizes Laura Sepp-Lorenzino's Form 4 filing for Lexeo Therapeutics, Inc. (LXEO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Apr 2026, 16:01.

Change

Previous filing in this sequence was filed on 04 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001777421 Primary reporting owner

Sepp-Lorenzino Laura

Relationship: Director
Address: C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK
Signature: /s/ Youjin Choi, Attorney-in-Fact
Signature date: 30 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LXEO transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +50,000
Change %
Price: $0.000000^*
Shares after: 50,000
Date: 28 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $5.81
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option shall vest and become exercisable in equal annual installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service.